PQUS0.210%
as of Jul 21
RMD
GrowthResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution.
Close · 3M
-21.48%
Held by 2 AI ETFs
AIVL0.210%
as of Jul 17
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
Buy signals11
Win rate18% (2/11)
Avg buy return-3.79%
PQUS · New entry · 1d
weight 0 → 0.210% (new)·stock up 2.6% in the 30 days before
Jul 17·entry $198.99·now $198.61Fresh
-0.19%
since Jul 17
AIVL · Weight increase · 2d
WisdomTree's AIVL fund, which uses AI to score names within a pre-filtered US value-factor pool, has notably increased its allocation to ResMed (RMD). The AI's decision to add weight, particularly at the current $198.99 price which is 68% of its 52-week high, suggests a deeper assessment beyond recent price dips. Its continuous analysis within the ~100 US value stock portfolio likely focused on RMD's fundamental strength, such as a 24.41% Return on Equity, to confirm genuine value and avoid a trap. This move aligns with the AI's role in distinguishing between potential bargains and underperforming assets, leveraging specific valuation metrics despite the stock's -19.5% 90-day return.
weight 0.205% → 0.212% (+0.007 pp)·stock up 5.2% in the 30 days before
Jul 16·entry $202.76·now $198.61Fresh
-2.05%
since Jul 16
AIVL · Weight decrease · 3d
AIVL's managed exposure to RMD exhibited a consistent, gradual reduction from July 8 through July 14, following a slight uptick in the preceding days. This pattern aligns with the ETF's periodic rebalancing mechanism for its ~100 US value stocks, rather than indicating an abrupt divestment. Despite RMD's 90-day price decline of 21.5% and its current price of $198.57 sitting at 68% of its 52-week high, the AI, which distinguishes genuine value from value traps within its pre-filtered universe, appears to have re-evaluated the stock. Its PBR of 6.34 and PER of 19.58, even alongside 24.41% ROE and 10.28% revenue growth, likely positioned it as less compelling for AIVL's specific value criteria relative to other opportunities. The recent 8.6% gain over the last 30 days may have further tempered its appeal within the fund's investment framework.
weight 0.221% → 0.205% (-0.016 pp)·stock up 0.3% in the 30 days before
Jul 14·entry $193.01·now $198.61
+2.90%
since Jul 14
AIVL · Weight decrease · 2d
RMD currently trades at $193.01, positioning it at 66% of its 52-week high, following significant declines of around 24% over both the 90-day and one-year periods, even with a recent 3.5% rebound. This price trajectory would typically attract traditional value investors, but AIVL’s AI manager is tasked with distinguishing true value from potential traps within its value-factor universe by analyzing fundamental and valuation metrics. Despite RMD’s 10.28% revenue growth and return on equity at 24.41%, its price-to-book ratio of 6.34 and price-to-earnings of 19.58 may indicate it did not sufficiently align with the AI's strict valuation criteria for a value proposition. Consequently, the fund executed a consecutive decrease in RMD’s weighting, declining from 0.2214% on July 9th to 0.2101% by July 13th, reflecting the AI's assessment that the stock, despite its lower price, posed a risk of being a value trap rather than a genuine value opportunity.
weight 0.221% → 0.210% (-0.011 pp)·stock up 2.5% in the 30 days before
Jul 13·entry $198.50·now $198.61
+0.06%
since Jul 13
AIVL · Accumulation · 5d
At $198.50, ResMed shares trade at 68% of their 52-week high, coming after a year-long decrease of 23.1% and a 90-day drop of 23.4%, despite a recent 4.2% bounce over the last month. This significant decline likely positioned RMD within AIVL's pre-filtered US value-factor pool, which seeks stocks trading at lower valuations. WisdomTree's AI component then distinguished RMD as a genuine value opportunity, assessing its 10.28% revenue growth and a 24.41% return on equity as indicators of fundamental strength, contrasting with its 19.58 PER and 6.34 PBR in light of the suppressed share price. Consequently, during its periodic rebalance around the end of June and early July, AIVL gradually increased its allocation to RMD, moving from 0.2062% to a peak of 0.2321% on July 7th before minor fluctuations, indicating confidence in its identified value proposition.
weight 0.206% → 0.216% (+0.010 pp)·stock up 3.5% in the 30 days before
Jul 10·entry $203.87·now $198.61Fresh
-2.58%
since Jul 10
AIVL · Accumulation · 5d
ResMed Inc.'s financial profile, featuring a 24.41% Return on Equity and 10.28% revenue growth, likely signaled to AIVL's AI a company with strong fundamental performance, a key consideration for its fundamental screening on margins and return on capital. Despite a P/E of 19.58 and a P/B of 6.34, the stock's recent price depreciation, reflected in a 90-day return of -21.1% and its current level at 69% of its 52-week high, presented a potential entry point within the ETF’s pre-filtered US value-factor universe. This context suggests the AI determined RMD was a genuine value opportunity, not a value trap, prompting AIVL’s gradual accumulation, with weights moving from 0.2062% at the end of June to 0.2321% by early July.
weight 0.213% → 0.221% (+0.009 pp)·stock up 7.9% in the 30 days before
Jul 9·entry $208.45·now $198.61Fresh
-4.72%
since Jul 9
AIVL · Accumulation · 5d
The ETF has displayed a series of incremental weight adjustments in RMD, leading to a general accumulation of the stock, with daily changes typically below one hundredth of a percentage point. This measured buying coincides with RMD's significant price decrease, having lost 19.0% over the last 90 days and trading at 71% of its 52-week high, aligning with AIVL's mandate to identify attractively priced stocks within its value-factor universe. WisdomTree's AI-driven methodology likely flagged ResMed as a genuine value opportunity, looking past recent market weakness, due to its underlying financial characteristics such as 10.28% revenue growth and a 24.41% return on equity. These fundamental indicators, analyzed by the AI, helped differentiate RMD from potential value traps, confirming its suitability for AIVL's portfolio even with its current PER of 19.58 and PBR of 6.34.
weight 0.210% → 0.220% (+0.010 pp)·stock up 5.0% in the 30 days before
Jul 8·entry $205.84·now $198.61Fresh
-3.51%
since Jul 8
AIVL · Accumulation · 5d
WisdomTree's AIVL ETF, which employs AI to score names within its pre-filtered US value-factor pool, appears to view RMD as a genuine value opportunity at its current price level. This strategy focuses on distinguishing durable businesses from potential value traps, informing the periodic rebalances across its portfolio of around 100 US stocks. Despite recent negative price momentum, with the stock down 20.2% over the last year and currently trading at 70% of its 52-week high, RMD's underlying financial characteristics, such as a 24.41% Return on Equity, likely align with the AI's criteria for capital efficiency. The gradual accumulation observed in RMD's weight from late June into early July aligns with the fund's periodic rebalancing cadence, allowing the AI to scale into positions deemed undervalued based on fundamentals and valuation metrics like P/E and P/B.
weight 0.211% → 0.232% (+0.021 pp)·stock up 13.1% in the 30 days before
Jul 7·entry $219.75·now $198.61Fresh
-9.62%
since Jul 7
AIVL · Accumulation · 5d
WisdomTree's AIVL fund, employing an AI to distinguish genuine value from value traps within its approximately 100 US value stocks, likely identified ResMed after its recent price deceleration. The significant 90-day return of -14.5% likely brought RMD into the fund's pre-filtered US value-factor pool. Subsequently, the AI's analysis of ResMed's fundamentals, such as its 24.41% ROE, indicated a fundamentally sound company rather than a deteriorating asset. This positive assessment, combined with the stock trading at 75% of its 52-week high, informed the gradual accumulation pattern observed, consistent with AIVL's periodic rebalancing schedule.
weight 0.206% → 0.230% (+0.024 pp)·stock up 17.1% in the 30 days before
Jul 6·entry $218.40·now $198.61Fresh
-9.06%
since Jul 6
AIVL · Accumulation · 5d
RMD’s P/E of 19.8 and P/B of 6.34 placed it within AIVL's pre-filtered US value-factor universe, while its 10.28% revenue growth and 24.41% ROE indicated underlying fundamental strength relevant to the fund's AI assessment of margins and return on capital. The AI component, designed to discern genuine value from potential traps, likely identified these metrics as supportive, preventing a 'value trap' designation despite the P/B ratio possibly appearing elevated for a traditional value fund. This gradual accumulation, observed from June 22nd to July 2nd, coincided with RMD’s current price of $209.63, a level approximately 71% of its 52-week high following a 17.4% one-year return decline. The significant share price depreciation over the prior 90 days and year likely signaled to the AI a specific buying opportunity, aligning a lower valuation with the company's sustained financial performance for inclusion in AIVL's portfolio of ~100 US value stocks.
weight 0.201% → 0.221% (+0.019 pp)·stock up 14.7% in the 30 days before
Jul 2·entry $209.63·now $198.61Fresh
-5.26%
since Jul 2
AIVL · Weight increase · 2d
Currently at $196.50, RMD trades at 67% of its 52-week high, having experienced declines of 22.2% over the past 90 days and 21.8% over the last year. Such a material price decline likely pushed the healthcare stock more prominently into the US value-factor pool from which AIVL selects its holdings. The AI component of this WisdomTree ETF specifically analyzes fundamentals like RMD's 10.28% revenue growth and 24.41% return on equity, alongside valuation metrics such as its 18.68 P/E ratio and 6.34 P/B ratio. The recent upward adjustment in RMD’s weight within AIVL, increasing from 0.2065% to 0.2113% between June 23rd and 24th, suggests the AI perceives a stronger value proposition at these price levels, distinguishing it from a value trap.
weight 0.201% → 0.211% (+0.010 pp)·stock down 5.6% in the 30 days before
Jun 24·entry $196.50·now $198.61Fresh
+1.07%
since Jun 24
AIVL · Weight decrease · 3d
WisdomTree's AIVL ETF, which leverages AI to select approximately 100 US value stocks and distinguish genuine value from potential traps, has been systematically reducing its allocation to RMD. The fund's AI algorithm, considering fundamentals like margins and return on capital alongside valuation metrics, appears to be re-evaluating RMD's profile despite the stock's recent price depreciation, including a 90-day return of -27.4%. While the price has fallen to 64% of its 52-week high, a PBR of 6.34 suggests the company's valuation relative to its book equity may still not align with the AI's preferred metrics for a pure value play within its pre-filtered universe. These consistent weight decreases, observed over multiple trading days within AIVL's periodic rebalance schedule, reflect the AI's ongoing assessment that RMD is no longer scoring as favorably for inclusion or weighting in the portfolio.
weight 0.210% → 0.201% (-0.009 pp)·stock down 10.2% in the 30 days before
Jun 22·entry $188.45·now $198.61
+5.39%
since Jun 22
AIVL · Weight decrease · 2d
AIVL has shown a pattern of gradual, often consecutive, reductions in its allocation to ResMed Inc., exemplified by the recent daily declines from 0.2103% to 0.2076% then to 0.2029% over a few trading days. This persistent trimming occurs even as ResMed's share price approaches its 52-week low of $182.82, following significant multi-month declines that place it at 64% of its 52-week high. AIVL's method of distinguishing genuine value from value traps within a pre-filtered US value-factor pool implies that while the stock trades at a lower price, the AI's assessment of its fundamental strength or its future prospects, particularly regarding metrics like its PBR of 6.34 despite a moderate PER of 18.12, is diminishing. Consequently, even with revenue growth at 10.28% and ROE at 24.41%, the AI-driven fund appears to be consistently decreasing its exposure, interpreting the stock's declining price as a sign of underlying issues rather than a more attractive entry point based on its proprietary scoring.
weight 0.210% → 0.203% (-0.007 pp)·stock down 9.2% in the 30 days before
Jun 18·entry $188.63·now $198.61
+5.29%
since Jun 18
AIVL · Weight increase · 2d
weight 0.205% → 0.218% (+0.013 pp)·stock down 6.5% in the 30 days before
Jun 5·entry $196.04·now $198.61Fresh
+1.31%
since Jun 5
AIVL · Weight decrease · 3d
The AI ETF likely initiated the consecutive weight decrease for RMD due to valuation concerns, specifically perceiving its high PBR as stretched relative to its ongoing revenue growth or identifying superior risk-adjusted opportunities elsewhere in the market. Retail investors should note that even fundamentally strong companies can face algorithmic rebalancing from sophisticated models if their valuation becomes extended, emphasizing the need for diversification and careful consideration of entry and exit points.
weight 0.234% → 0.222% (-0.013 pp)·stock down 13.2% in the 30 days before
May 11·entry $198.76·now $198.61
-0.08%
since May 11
AIVL · Weight decrease · 2d
The AI likely initiated a consecutive weight decrease for RMD due to its relatively high valuation metrics (PER 19.23, PBR 6.34), suggesting the stock may be fully priced or overvalued in the current market environment, despite its strong revenue growth and ROE. For retail investors, this pattern signals a need to critically reassess RMD's current valuation against its industry and historical performance, and to investigate any recent company or sector news that might be driving the AI's cautious stance.
weight 0.234% → 0.232% (-0.003 pp)·stock down 9.3% in the 30 days before
May 8·entry $206.76·now $198.61
-3.94%
since May 8
AIVL · New entry · 1d
The AI ETF likely added ResMed due to its exceptional 24.81% Return on Equity and solid 9.57% revenue growth, signaling strong profitability and efficient management. For retail investors, this emphasizes the value of scrutinizing both robust profitability metrics and consistent top-line growth, which are key indicators for advanced algorithmic stock selection.
weight 0 → 0.241% (new)·stock down 4.8% in the 30 days before
Apr 30·entry $213.81·now $198.61Fresh
-7.11%
since Apr 30
Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.